





NATIONAL RESEARCH CENTER FOR

HEALTH DISPARITIES

2300 Georgia Ave NW Washington, DC 20001









DESIGNED FOR DISCOVERY, FUELED BY PURPOSE











OUR MISSION



OUR MISSION

LAB AND OFFICE SPACE FOR LIFE-CHANGING RESEARCH

At the National Research Center for Health Disparities, innovators in science and medicine will work together to develop solutions to diseases that affect systematically marginalized communities worldwide.

The first phase of the Research Center will provide 206,398 square feet of industry-leading laboratory and office space—designed to empower incubators, established biotechnology/pharmaceutical companies, non-profits/foundations, and policymakers focused on addressing health disparities.

The laboratory and office spaces will be flexible, allowing easy move in and quick expansion of tenants' operations.

Collaboration areas will encourage and enable Research
Center users to share ideas, engage with community members, raise awareness of critical initiatives, engage with federal and state policymakers, and provide information

on obstacles to and solutions for achieving equity within our healthcare system. Future phases will offer expansion opportunities up to 160,000 square feet.

Situated in Washington's lively Shaw neighborhood and immediately adjacent to the campus of historic Howard University, the Research Center will offer organizations and their workforce the ability to partner with the University's College of Medicine, hospital, and extensive undergraduate and graduate public health and STEM programs to foster the next generation of talent.



NRCHD ADVISORY COUNCIL

The National Research Center for Health Disparities will be a landmark lab space and keystone location for leaders in this vital effort.

Additional members to be named in the future

MEMBERS



Dr. Wayne A.I. Frederick

PRESIDENT EMERITUS

Howard University



Dr. Francis Collins

FORMER DIRECTOR

NIH



Dr. Reed Tuckson

FORMER CHIEF MEDICAL OFFICER

UnitedHealth



Trustee Kevin Lofton

BOARD MEMBER

Gilead

The National Research Center for Health Disparities will foster collaboration between Howard University faculty and companies, non-profits, and foundations who will work together on the research and development of innovative solutions, including addressing health disparities and discovering new drugs and cutting-edge therapies."

Dr. Wayne A.I. Frederick, President, Howard University



Dr. Harriet Washington

AUTHOR & LECTURER IN BIOETHICS

Columbia University



Dr. Dorothy E. Roberts

PROFESSOR OF LAW & SOCIOLOGY

UPENN



Dr. Karen E. Knudsen

CEO

American Cancer Society



Dr. David Williams

CHAIR, DEPARTMENT OF SOCIAL & BEHAVIORAL SCIENCES

Howard University



Health disparities are complex, urgent challenges that directly impact millions of lives daily. Addressing disparities in health outcomes and achieving the highest level of health for all people—regardless of race, ethnicity, age, gender, or individual characteristics—requires collaboration from every part of the healthcare system. Government policymakers, hospitals, pharmaceutical companies, innovative start-ups, health-focused non-profits, and healthcare organizations all have a critical role in removing barriers to health equity. The National Research Center for Health Disparities will be a landmark lab space and keystone location for leaders in this vital effort.

CANCER MORTALITY RATE

Compared to other racial and ethnic groups, Black Americans have the **highest mortality** rate for all cancers combined. PRESSURE AND STROKE RISK

Black Americans are **1.4 times as likely to have high blood pressure** as non-Hispanic White Americans and 60% more likely to have a stroke.



03 DIABETES RATES

American Indians, Alaska Natives (AIAN) and Black Americans are **twice as likely to have diabetes** than non-Hispanic White Americans of similar age.

04

LIFE EXPECTANCY

As of 2018, life expectancy among Black Americans was four years lower than White Americans, with the lowest expectancy among Black American men.

05 INFANT MORTALITY

Black Americans have **2.4 times the infant mortality rate** as non-Hispanic White Americans.



06 MATERNAL HEALTH

Black women are three times more likely to die from pregnancy-related causes than White women; the pregnancy-related mortality rate for Black women aged 30-34 is four times that of White women.

SICKLE CELL ANEMIA

About 1 in 13 Black or African-American babies is born with the sickle cell trait. The average life expectancy for people with the most severe form of SCD is 30 years shorter than those without SCD.

BIG PHARMA'S BIG CHALLENGE

Pfizer

"Pfizer and many others have been working for a long time to try to address the barriers that limit health equity. While important progress has been made, we must challenge the norm."



Albert Bourla

CEO, PFIZER

ر^{ااا} Bristol Myers Squibb™

"We are acutely aware of the role that access to our medicines can play in improving the lives of patients and their families, which is why we are doing all we can to ensure greater health equity... Our focus on inclusion and diversity is at the very heart of who we are as a company... we won't rest until true health equity is a reality."



Giovanni Caforio

CEO, BRISTOL MYERS SQUIBB

Medtronic

"Health systems are part of the problem. We need to be a part of the solution. One area that we can contribute to is in the area of technology. Medtronic can uniquely look out for patient populations that are underserved and underresourced and bring technology to them."



Dr. John de Csepel

CHIEF MEDICAL
OFFICER, MEDTRONIC

Johnson & Johnson

"Events in recent years, as well as startling statistics on equity around the world, have kick-started long overdue conversations about the impact of systemic racism on health outcomes.

Our approach to DEI is constantly evolving and growing to anticipate and address these urgent needs."



Joaquin Duato

CEO, JOHNSON & JOHNSON

Genentech

"We can no longer accept this status quo. To break this cycle of inequity and create a world where all patients can access investigational medicines, we must come together as industry leaders to take bold and decisive action."



Quita Highsmith

VICE PRESIDENT
AND CHIEF
DIVERSITY OFFICER,
GENENTECH



"We must strengthen our current efforts to create an inclusive culture and expand our work to address health disparities and their root causes."



Greg A. Adams

CHAIRMAN AND CEO, KAISER PERMANENTE

illumına

"We have a moral imperative to increase the visibility of this global health problem and help find solutions for the children and families who are suffering."



Francis deSouza

PRESIDENT AND CEO, ILLUMINA

Takeda

"To solve for the inequities that exist today, we need to be able to address the social determinants of health, including economic stability and education, and ensure that patients who need medicines can access them. While this endeavor is vast, we can all agree on both the moral and business imperative for addressing health inequities. And, as business leaders, it is our role to help drive this change by embedding health equity into every aspect of decision-making."



Christophe Weber

CEO, TAKEDA



MISSION-DRIVEN COLLABORATION WITH HOWARD UNIVERSITY

Howard University's planned \$1.4 billion investment in a new hospital, health sciences complex, and STEM center—all to be completed by 2026—will be a key addition to the existing life sciences infrastructure at the University and in greater Washington, D.C.

HOWARD'S HEALTH
COMMITMENT &
INVESTMENT

\$785M

in New Academic Facilities

\$650M

in New Howard University Hospital

#2

University for PhDs Awarded to Black Scholars \$122M

in Research Fundraising FY 2022

#1

Training Institution for Minority
Physicians









LOCATION OVERVIEW



D.C.-MARYLAND BIOTECH REGION

THE D.C. REGION IS A WORLD-RENOWNED LIFE SCIENCE ECOSYSTEM.

#2 U.S. MARKET IN SIZE

35M SF of R&D & GMP Space

#2 U.S. MARKET IN TALENT

1 of 4 U.S. Markets with >25K Scientists

#3 in Annual Science Degrees (4,500+)

#4
U.S. MARKET IN
FUNDING


\$2.9B in NIH Funding (Fiscal Year 2022)

\$882M in Venture Capital Funding











15.6M SF

PRIVATE SECTOR TENANCY



AstraZeneca



BIONTECH











GSK



Johns Hopkins University





























19.2M SF

PUBLIC HEALTH AGENCY LABS





















WORLD-CLASS UNIVERSITIES & COLLEGES





























PUBLIC HEALTH NON-PROFITS



















THE CAPITAL CLUSTER

THE NATIONAL RESEARCH
CENTER WILL BE A KEYSTONE
LOCATION FOR LIFE SCIENCES,
NON-PROFITS, FOUNDATIONS,
AND POLICY MAKERS FOCUSED
ON HEALTH DISPARITIES IN THE
DISTRICT OF COLUMBIA.

With the ability to capitalize on NIH, DC, federal, venture capital, and other significant funding sources, Research Center tenants taking advantage of the location and mission will drive the continued growth of the Eds and Meds and public policy cluster in the region and the city. With its proximity to Congress, the Executive Branch, the U.S. Department of Health and Human Services, and the National Institutes of Health, the Research Center offers tenants unique access to policymakers and the opportunity to create positive change at the highest levels.





BE IN THE CENTER OF IT ALL

THE NATIONAL RESEARCH CENTER FOR HEALTH DISPARITIES WILL BE EMBEDDED IN THE SHAW/U STREET CORRIDOR—THE DISTRICT'S DINING, SHOPPING, ENTERTAINMENT, AND CULTURAL HEART.

The Research Center will have direct access to public transportation, allowing tenants to seamlessly navigate a city with endless possibilities.

3 MIN

U STREET
METRO STATION

40 MIN

DULLES INTERNATIONAL AIRPORT **15 MIN**

REAGAN NATIONAL AIRPORT

15 MIN

UNION STATION TRANSIT SCORE (EXCELLENT TRANSIT)































BUILDING SPECIFICATIONS

OVERVIEW		
ADDRESS	2300 Georgia Avenue NW	
BUILDING TYPE	Purpose-built lab & research	
BUILDING SIZE	206,398 SF	
LAND AREA	44,000 SF	

BUILDING STRUCTURE			
STRUCTURE	Concrete		
FOUNDATION	Piles		
FLOOR-TO-FLOOR HEIGHT			
2ND-6TH FLOORS	15'0"		
TYPICAL DESIGN FLOOR LIVE LOAD			
LAB/OFFICE	100lbs/PSF		
MECHANICAL	150lbs/PSF		
COLUMN SPACING	22' x 35' typical bay		
LOADING	4 bays		

ELECTRIC CAPACITY	
LAB	12 W/RSF
OFFICE	4-5 W/RSF
LAB SUPPORT	20 W/RSF
EMERGENCY BACK-UP	5 W/RSF

MECHANICAL SYSTEMS		
LAB	1.6 CFM/SF	
OFFICE	0.3 CFM/SF	
PARKING RATIO	0.5 spaces/1,000 SF	

ESG INITIATIVES		
EV CHARGING STATIONS	10	
LEED GOLD INITIATIVE		

STACKING PLAN Amenity **TOTAL BUILDING SPACE** LEVEL 179,000 RSF 6 5 **AMENITY** 9,823 RSF LEVEL **LEVEL 2-6** LEVEL 31,569 RSF 15' Floor-to-Floor LEVEL **LEVEL I** 11,502 RSF Retail Retail Retail 100+ Parking Lobby **Spaces P2**

P1



Lobby Level


II,502 RSF

- LOBBY
- RETAIL
- CORRIDOR
- LAB
- SUPPORT



Rooftop Amenities

9,823 RSF





FLOORS 2-6 HYPOTHETICAL LAYOUTS: 31,569 RSF

Research & Development

31,569 RSF

- OFFICE
- LAB
- CORRIDOR
- SUPPORT
- SWING SPACE.

 MEP DESIGNED TO

 SUPPORT LAB OR

 OFFICE



Office

31,569 RSF

- OFFICE
- PRIVATE OFFICE
- CORRIDOR
- OFFICE SUPPORT
- MEETING SPACE





DEVELOPMENT TIMELINE

Lead Tenants'
Lease
Executions

MONTH 2

Finalize
Preconstruction
& Design

MONTH 5

Building Permits Received **MONTH 7**

Construction Commences





MONTH 25

Start Tenant Buildout MONTH 31

Complete Base Building **→ MONTH 34**

Tenant Occupancy







FOR LEASING INFORMATION, PLEASE CONTACT:

FRANK GRAYBEAL

+1 301 215 4114 FRANK.GRAYBEAL@CBRE.COM

TOMMY CLEAVER

+1 202 585 5544 THOMAS.CLEAVER@CBRE.COM

KEVIN REAP

+1 301 215 4109 KEVIN.REAP@CBRE.COM

DAN GRIMES

+1 202 585 5731 DAN.GRIMES@CBRE.COM













